PMID- 31944872
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
VI  - 26
IP  - 2
DP  - 2020 Feb
TI  - World Health Organization Essential Medicines List: Multiple sclerosis 
      disease-modifying therapies application.
PG  - 153-158
LID - 10.1177/1352458519898340 [doi]
AB  - INTRODUCTION: The World Health Organization (WHO) publishes a biennial Essential 
      Medicines List (EML) to assist governments in low-resource settings to prioritize 
      their spending on medicines. Currently, no medicines on the EML have a multiple 
      sclerosis (MS) indication. Multiple Sclerosis International Federation (MSIF) 
      prepared an application for inclusion of MS disease-modifying therapies (DMTs) 
      for the 2019 EML together with the regional Committees for Treatment and Research 
      in Multiple Sclerosis (TRIMS) and the World Federation of Neurology. RATIONALE: 
      The MSIF taskforce categorized 15 DMTs according to their efficacy and risk 
      profiles to ensure the ability to treat as many different clinical scenarios as 
      possible. Three DMTs were selected: glatiramer acetate, fingolimod, and 
      ocrelizumab. OUTCOME: The WHO Expert Committee did not recommend the addition of 
      any of the DMTs to the EML. They acknowledged the public health burden of MS, the 
      need for effective and affordable MS medications, and the high volume of letters 
      received in support of the application but requested a revised application. 
      DISCUSSION: Despite the negative outcome, the repeated recognition of MS as a 
      global public health burden is sending a powerful message to governments globally 
      that a range of affordable and good quality medications need to be available to 
      health systems and people affected by MS.
FAU - McDonell, Jennifer
AU  - McDonell J
AD  - Multiple Sclerosis Society of Canada, Toronto, ON, Canada.
FAU - Costello, Kathleen
AU  - Costello K
AD  - National Multiple Sclerosis Society, New York, NY, USA.
FAU - Laurson-Doube, Joanna
AU  - Laurson-Doube J
AD  - Multiple Sclerosis International Federation, London, UK.
FAU - Rijke, Nick
AU  - Rijke N
AD  - Multiple Sclerosis International Federation, London, UK.
FAU - Giovannoni, Gavin
AU  - Giovannoni G
AD  - Blizard Institute, Queen Mary University of London, Barts and The London School 
      of Medicine, London, UK.
FAU - Banwell, Brenda
AU  - Banwell B
AD  - Department of Pediatric Neurology, Children's Hospital of Philadelphia, 
      Philadelphia, PA, USA.
FAU - Baneke, Peer
AU  - Baneke P
AD  - Multiple Sclerosis International Federation, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200116
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Humans
MH  - Immunologic Factors/*therapeutic use
MH  - Multiple Sclerosis/*drug therapy
MH  - *World Health Organization
OTO - NOTNLM
OT  - Essential Medicines List
OT  - Multiple sclerosis
OT  - access to treatment
OT  - disease-modifying therapies
EDAT- 2020/01/17 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/01/17 06:00
PHST- 2020/01/17 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/01/17 06:00 [entrez]
AID - 10.1177/1352458519898340 [doi]
PST - ppublish
SO  - Mult Scler. 2020 Feb;26(2):153-158. doi: 10.1177/1352458519898340. Epub 2020 Jan 
      16.